One Protein Made Aging Mice Stronger and Healthier

Aging mice grew stronger, walked better, and developed healthier bones after scientists boosted levels of a single protein that fights chronic inflammation.

Researchers at the University at Buffalo focused on a protein called tristetraprolin, or TTP, which naturally declines as we age. This protein acts like a cleanup crew, breaking down inflammatory signals before they can damage tissues and weaken the body.

The team genetically modified 22-month-old mice (considered elderly) to maintain stable TTP levels. The results, published in January 2026, were striking.

Male mice with higher TTP showed dramatically lower frailty scores than untreated mice. They gripped harder, walked faster, lasted longer on treadmills, and had more energy overall.

"These mice had healthier bones and reduced bone breakdown," says Keith Kirkwood, who led the six-year study supported by $2.1 million from the National Institutes of Health. "They exhibited a more youthful-looking immune profile."

Female mice also improved, though less dramatically than males. Researchers believe this may relate to declining estrogen levels and smaller body size affecting how tissues respond to anti-inflammatory changes.

The timing matters because America is aging rapidly. By 2050, nearly one in four Americans will be 65 or older, with many living into their 90s.

While modern medicine has extended how long we live, aging still brings serious challenges: weaker immunity, bone loss, fatigue, and declining strength. About 15% of Americans over 65 who don't live in nursing homes experience frailty.

Why This Inspires

This research targets what scientists call "inflammaging," the constant low-level inflammation that gradually damages our bodies as we age. Instead of treating individual symptoms, boosting TTP could address multiple age-related problems at once.

The protein works fast, breaking down inflammatory signals within minutes rather than hours. This rapid response helps prevent inflammation from spreading throughout the body.

Human treatments remain years away. Early drug screening hasn't yet identified compounds that successfully boost TTP expression in people.

But the research team is already planning their next steps. They want to explore whether TTP could reduce brain inflammation linked to dementia and Alzheimer's disease.

"I'm optimistic about where this research could lead and what we may learn as studies continue over time," Kirkwood says.

For millions of Americans hoping to stay active and independent as they age, this tiny protein could represent a powerful ally in the fight against frailty.